Literature DB >> 23050104

Clinical utility of circulating tumor cells in non-small-cell lung carcinoma: are we there yet?

Milica Kontic1, Miodrag Ognjanovic, Dragana Jovanovic, Simona Ognjanovic.   

Abstract

Entities:  

Year:  2012        PMID： 23050104      PMCID： PMC3461066          DOI： 10.3978/j.issn.2072-1439.2012.08.22

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.

Authors:  Véronique Hofman; Marius I Ilie; Elodie Long; Eric Selva; Christelle Bonnetaud; Thierry Molina; Nicolas Vénissac; Jérôme Mouroux; Philippe Vielh; Paul Hofman
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

2.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

3.  Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study.

Authors:  Ruth L Katz; Weigong He; Abha Khanna; Ricardo L Fernandez; Tanweer M Zaidi; Matthew Krebs; Nancy P Caraway; Hua-Zhong Zhang; Feng Jiang; Margaret R Spitz; David P Blowers; Carlos A Jimenez; Reza J Mehran; Stephen G Swisher; Jack A Roth; Jeffrey S Morris; Carol J Etzel; Randa El-Zein
Journal:  Clin Cancer Res       Date:  2010-07-22       Impact factor: 12.531

Review 4.  Circulating tumor cells (CTC) detection: clinical impact and future directions.

Authors:  Patrizia Paterlini-Brechot; Naoual Linda Benali
Journal:  Cancer Lett       Date:  2007-02-20       Impact factor: 8.679

5.  Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Authors:  Elizabeth A Punnoose; Siminder Atwal; Weiqun Liu; Rajiv Raja; Bernard M Fine; Brett G M Hughes; Rodney J Hicks; Garret M Hampton; Lukas C Amler; Andrea Pirzkall; Mark R Lackner
Journal:  Clin Cancer Res       Date:  2012-04-05       Impact factor: 12.531

6.  Circulating tumor cell isolation and diagnostics: toward routine clinical use.

Authors:  Anja van de Stolpe; Klaus Pantel; Stefan Sleijfer; Leon W Terstappen; Jaap M J den Toonder
Journal:  Cancer Res       Date:  2011-09-06       Impact factor: 12.701

7.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Authors:  Tanja Fehm; Arthur Sagalowsky; Edward Clifford; Peter Beitsch; Hossein Saboorian; David Euhus; Songdong Meng; Larry Morrison; Thomas Tucker; Nancy Lane; B Michael Ghadimi; Kerstin Heselmeyer-Haddad; Thomas Ried; Chandra Rao; Jonathan Uhr
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

8.  Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Authors:  Pamela L Paris; Yasuko Kobayashi; Qiang Zhao; Wei Zeng; Shivaranjani Sridharan; Tina Fan; Howard L Adler; Emmanuel R Yera; M H Zarrabi; Stanley Zucker; Jeffry Simko; Wen-Tien Chen; Jonathan Rosenberg
Journal:  Cancer Lett       Date:  2009-01-21       Impact factor: 8.679
  8 in total
  1 in total

1.  A preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer.

Authors:  Milica Kontic; Miodrag Ognjanovic; Dragana Jovanovic; Marko Kontic; Simona Ognjanovic
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.